Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/hl7-eu/gravitate-health/ and changes regularly. See the Directory of published versions
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
What is in this leaflet
Suliqua is an injectable diabetes medicine that contains two active substances:
insulin glargine: a long-acting type of insulin which helps control blood sugar (glucose) throughout the day.
lixisenatide: a “GLP-1 analogue” that helps the body produce its own additional insulin in response to increases in blood sugar, and slows the absorption of sugar from foods.
Suliqua is used to treat adults with type 2 diabetes, to help control blood sugar levels when they are too high, it is an adjunct to diet and exercise. It is given, with metformin with or without sodium- glucose co-transporter-2 (SGLT2) inhibitors (gliflozin products), when other medicines are not enough on their own to control your blood sugar levels.
Do not use Suliqua:
Warnings and precautions
Talk to your doctor, pharmacist or nurse before using Suliqua if:
Follow closely your doctor’s instructions for dose, monitoring (blood and urine tests), diet and physical activity (physical work and exercise) and injection technique.
Be especially aware of the following:
While using this medicine be aware of the following and talk to your doctor, pharmacist or nurse before using Suliqua:
Skin changes at the injection site The injection site should be rotated to prevent skin changes such as lumps under the skin. The insulin may not work very well if you inject into a lumpy area (see How to use Suliqua). Contact your doctor if you are currently injecting into a lumpy area before you start injecting in a different area. Your doctor may tell you to check your blood sugar more closely, and to adjust your insulin or your other antidiabetic medicine dose.
Travel
Talk to your doctor before travelling. You may need to talk about:
Children and adolescents
There is no experience with Suliqua in children and adolescents aged less than 18 years; therefore, the use of Suliqua is not recommended in this age group.
Other medicines and Suliqua
Tell your doctor, pharmacist or nurse if you are using, have recently used or might use any other medicines. If you use another antidiabetic medicine, discuss with your doctor whether you should stop using that medicine when starting Suliqua.
Some medicines can change your blood sugar level. This may mean your doctor may need to change your Suliqua dose. So, before taking a medicine ask your doctor if it will affect your blood sugar and what action, if any, you need to take. You also need to be careful when you stop taking a medicine.
The effect of some medicines you swallow might be affected by Suliqua. Some medicines such as antibiotics, oral contraceptives, statins (medicines like atorvastatin to lower cholesterol), gastro-resistant tablets or capsules or granules or oral powder or suspensions that should not stay too long in your stomach may need to be taken at least one hour before or four hours after your Suliqua injection.
Your blood sugar level may fall (hypoglycaemia) if you take:
Your blood sugar level may rise (hyperglycaemia) if you take:
Your blood sugar level may either rise or fall if you take:
Medicine that may reduce warning signs of low blood sugar
Beta-blockers and some other medicines (such as clonidine, guanethidine, reserpine – for high blood pressure) may make it harder to recognise warning signs of your low blood sugar levels (hypoglycaemia). It can even hide or stop the first signs that your blood sugar is too low.
If any of the above apply to you (or you are not sure), talk to your doctor, pharmacist or nurse before using this medicine.
Warfarin or other anticoagulants
Tell your doctor if you are taking warfarin or other anticoagulants (medicines used to prevent clotting of the blood) as you might need to have more frequent blood tests (called ‘International Normalised Ratio’ or INR test) to check your blood clotting.
Suliqua with alcohol
Your blood sugar level may either rise or fall if you drink alcohol. You should check your blood sugar level more often.
Pregnancy and breast-feeding
Suliqua should not be used during pregnancy. It is not known if Suliqua harms your unborn child. Suliqua should not be used if breast-feeding. It is not known if Suliqua passes into your milk. If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Driving and using machines Having too low or too high blood sugar (see information in the box at the end of this leaflet) can affect your ability to drive and use tools or machines. Your concentration may be affected. This could be dangerous to yourself and others.
Ask your doctor whether you can drive if:
Suliqua contains sodium
This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodium-free’.
Suliqua contains metacresol
This medicine contains metacresol which may cause allergic reactions.
Always use this medicine exactly as your doctor has told you. Your doctor may tell you to use a different dose of Suliqua compared to your previous insulin dose or glucose lowering medicine if any. Check with your doctor, pharmacist or nurse if you are not sure.
Based on your lifestyle, your blood sugar tests and your previous insulin use, your doctor will tell you:
How much to use
Suliqua 100 units/ml + 50 micrograms/ml solution for injection in pre-filled pen:
Your dose of Suliqua is administered as ‘dose steps’. The dose window on the pen shows the number of dose steps.
Do not inject a dose lower than 10 dose steps. Do not inject a dose higher than 40 dose steps. If a dose greater than 40 dose steps is needed, your doctor will prescribe a different strength. For dose steps from 30-60 units, Suliqua 100 units/ml + 33 micrograms/ml solution for injection in pre-filled pen is available.
Many factors may affect your blood sugar level. You should know what they are so that you can take the right action if your blood sugar level changes and help stop it becoming too high or too low. See the box at the end of this leaflet for more information.
Use in elderly patients (65 years and older) If you are 65 years or older, talk to your doctor as you may need a lower dose.
If you have kidney or liver problems
If you have kidney or liver problems, talk to your doctor as you may need a lower dose.
When to inject Suliqua
Use Suliqua once a day, within 1 hour before a meal. Preferably inject Suliqua before the same meal every day, when you have chosen the most convenient meal.
Before injecting Suliqua
How to inject
Do not use Suliqua
Other important information about using the pre-filled pens
Never use a syringe to remove the solution from the pen to avoid dosing errors and potential overdose.
If the pen is damaged, has not been stored correctly, if you are not sure that it is working properly or you notice that your blood sugar control is unexpectedly getting worse:
If you use more Suliqua than you should
If you have injected too much of this medicine, your blood sugar level may become too low (hypoglycaemia). Check your blood sugar and eat more food to prevent your blood sugar getting too low (hypoglycaemia). If your blood sugar gets too low, see the advice in the box at the end of this leaflet.
If you forget to use Suliqua
If you have missed a dose of Suliqua or if you have not injected enough insulin, your blood sugar level may become too high (hyperglycaemia): When needed, Suliqua can be injected before the next meal.
If you stop using Suliqua
Do not stop using this medicine without talking to your doctor. If you do, it could lead to very high blood sugar (hyperglycaemia) and a build-up of acid in the blood (ketoacidosis).
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
If you notice signs of your blood sugar being too low (hypoglycaemia), take action to increase your blood sugar level straightaway (see the box at the end of this leaflet). Hypoglycaemia can be very serious and is very common with medicines containing insulin (may affect more than 1 in 10 people). Low blood sugar means that there is not enough sugar in your blood. If your blood sugar falls too low, you may pass out (become unconscious). If blood sugar remains very low for too long it may cause brain damage and may be life-threatening. For more information, see the box at the end of this leaflet.
Other side effects
Tell your doctor, pharmacist or nurse if you notice any of the following side effects:
Skin changes at the injection site
If you inject insulin too often at the same place, the skin may either shrink (lipoatrophy) or thicken (lipohypertrophy). Lumps under the skin may also be caused by build-up of a protein called amyloid (cutaneous amyloidosis). This is not known how often these skin changes occur. The insulin may not work very well if you inject into a lumpy area. Change the injection site with each injection to help prevent these skin changes.
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1,000 people)
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and on the label of the pen after “EXP”. The expiry date refers to the last day of that month.
Before first use
Store in a refrigerator (2°C-8°C). Do not freeze or place next to the freezer compartment or a freezer pack. Keep the pen in the outer carton in order to protect from light.
After first use
Store your pen in use below 25°C for a maximum of 28 days. Discard the pen after this period. Do not return the pen to a refrigerator and do not freeze. Store the pen away from direct heat or direct light. Always keep the cap on the pen when you are not using it in order to protect it from light. Do not leave the pen in a car on an exceptionally warm or cold day.
Do not store the pen with the needle attached.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer used. These measures will help protect the environment.
What Suliqua contains
What Suliqua looks like and contents of the pack
Suliqua is a clear and colourless solution for injection (injection) filled in a glass cartridge inserted in a pre-filled pen (SoloStar).
Pack sizes of 3, 5 and 10 pre-filled pens.
Not all pack sizes may be marketed.
Marketing Authorisation Holder
Sanofi Winthrop Industrie 82 avenue Raspail
94250 Gentilly
France
Manufacturer
Sanofi-Aventis Deutschland GmbH
Industriepark Höchst - 65926 Frankfurt am Main
Germany
Full name: Suliqua 100 units/ml + 50 micrograms/ml solution for injection in a pre-filled pen
- Invented name part: Suliqua
- Scientific name part: Insulin glargine, Lixisenatide
- Strength part: 100 units/ml + 50 ug/ml
- Pharmaceutical dose form part: Solution for injection
Name usage: English (Denmark)
Authorised dose form:
Legal status of supply: Medicinal product subject to medical prescription
Domain: Human use
Resource status: active
Product classification:
Package 1 of 3
PMSWI: EU/1/16/1157/001
Description:
Marketing status:
Pack size:
Package: 1 Box (Cardboard)
Containing:
Package: 3 Pre-filled pen (Glass type I)
Containing:
Manufactured Item
Dose form: Solution
Unit of presentation: Pen
Ingredient
Role: Active
Substance: Insulin glargine
Ingredient
Role: Active
Substance: Lixisenatide
Ingredient
Role: Excipient
Substance: GLYCEROL 85% [WHO-DD]
Ingredient
Role: Excipient
Substance: Methionine
Ingredient
Role: Excipient
Substance: Metacresol
Ingredient
Role: Excipient
Substance: Zinc chloride
Ingredient
Role: Excipient
Substance: HYDROCHLORIC ACID [IARC]
Ingredient
Role: Excipient
Substance: STERILE WATER FOR INJECTION
Ingredient
Role: Excipient
Substance: Sodium hydroxide
Package 2 of 3
PMSWI: EU/1/16/1157/002
Description:
Marketing status:
Pack size:
Package: 1 Box (Cardboard)
Containing:
Package: 5 Pre-filled pen (Glass type I)
Containing:
Manufactured Item
Dose form: Solution
Unit of presentation: Pen
Ingredient
Role: Active
Substance: Insulin glargine
Ingredient
Role: Active
Substance: Lixisenatide
Ingredient
Role: Excipient
Substance: GLYCEROL 85% [WHO-DD]
Ingredient
Role: Excipient
Substance: Methionine
Ingredient
Role: Excipient
Substance: Metacresol
Ingredient
Role: Excipient
Substance: Zinc chloride
Ingredient
Role: Excipient
Substance: HYDROCHLORIC ACID [IARC]
Ingredient
Role: Excipient
Substance: STERILE WATER FOR INJECTION
Ingredient
Role: Excipient
Substance: Sodium hydroxide
Package 3 of 3
PMSWI: EU/1/16/1157/005
Description:
Marketing status:
Pack size:
Package: 1 Box (Cardboard)
Containing:
Package: 10 Pre-filled pen (Glass type I)
Containing:
Manufactured Item
Dose form: Solution
Unit of presentation: Pen
Ingredient
Role: Active
Substance: Insulin glargine
Ingredient
Role: Active
Substance: Lixisenatide
Ingredient
Role: Excipient
Substance: GLYCEROL 85% [WHO-DD]
Ingredient
Role: Excipient
Substance: Methionine
Ingredient
Role: Excipient
Substance: Metacresol
Ingredient
Role: Excipient
Substance: Zinc chloride
Ingredient
Role: Excipient
Substance: HYDROCHLORIC ACID [IARC]
Ingredient
Role: Excipient
Substance: STERILE WATER FOR INJECTION
Ingredient
Role: Excipient
Substance: Sodium hydroxide
Administrable Product (1 of 1)
Dose form: Solution
Unit of presentation: Pen
Route of administration:
Ingredient
Role: Active
Substance: Insulin glargine
Ingredient
Role: Active
Substance: Lixisenatide
Ingredient
Role: Excipient
Substance: GLYCEROL 85% [WHO-DD]
Ingredient
Role: Excipient
Substance: Methionine
Ingredient
Role: Excipient
Substance: Metacresol
Ingredient
Role: Excipient
Substance: Zinc chloride
Ingredient
Role: Excipient
Substance: HYDROCHLORIC ACID [IARC]
Ingredient
Role: Excipient
Substance: STERILE WATER FOR INJECTION
Ingredient
Role: Excipient
Substance: Sodium hydroxide